The Novo Nordisk share has experienced a bitter setback in the past few weeks. Disappointing quarterly results dropped the course further. Now a recovery begins.
• Disappoint Novo Nordisk Quartals figures
• A share recovers on Thursday
• New CEO relies on the change of course
The investors of the Novo Nordisk share can look back on further disappointing development. On August 6, 2025, the company reported the results for the second quarter: Novo Nordisk has earned less than expected, although the weight loss has been more likely to perform than predicted. The operational result was 33.5 billion DKK below expectations, as was the net profit with DKK 26.5 billion. The annual forecasts that have already been reduced were confirmed.
The shares of the diabetes specialist then fell to the deepest in Copenhagen for four years and closed with a minus of 5.36 percent at 289.50 DKK. Since the record high of over 1,000 crowns, which was reached over a year ago in the course of the hypes at that time around weight loss medication, the trend has been shown significantly down. However, a recovery begins on Thursday: the course in Copenhagen temporarily increases by strong 12.18 percent to 324.75 DKK. The reason for this is probably the disappointing study results of competitor Eli Lilly, as DPA-AfX reports. In a phase III study, the company published the first results on the Orforglipron weight pills. Although all primary and secondary endpoints were reached, the average weight loss of a good 11 percent remained behind the expectations and is under the effectiveness of Nordisks Wegovy.
Analysts evaluate the situation of Novo Nordisk according to the dpa-AfX: JPMorgan remains confident with his classification “Overweight”. The UBS sticks to its neutral evaluation, while Jefferies with “Under Perperform” represents a more reserved assessment.
Novo Nordisk share puts pressure on growing competition
The decline in the past few days is only the continuation of a massive burglary that has already been initiated. On July 29, 2025, Novo Nordisk shocked the market with a winning warning that had the stock collapsed by about 30 percent.
The main driver for the current pressure on Novo Nordisk is the intensive competition. The company’s core business, which specializes in medication such as Ozempic and Wegovy in the field of diabetes and weight management, is confronted with a wave of new competing products. These alternative preparations exert considerable pressure on the market shares and the pricing of Novo Nordisk, which directly affects the earnings forecasts and worries investors. The winning warning in July was a direct reaction to this tightened market dynamics.
New CEO relies on the change of course
In response to the challenging market situation and the considerable loss of value, Novo Nordisk, led by the new CEO Mike Dustdar, plans to take measures to increase efficiency and to improve commercial orientation. The aim is to better use the growth potential of the existing product portfolios and to counteract competitive pressure. These strategic adjustments could be crucial to regain the trust of investors and to secure the company’s long -term profitability. It remains to be seen which specific steps the new CEO will initiate and whether they are sufficient to stop the negative trend.
Editor finance.net
Selected leverage products on Novo Nordisk
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Novo Nordisk
The lever must be between 2 and 20
Advertising